Last reviewed · How we verify

SOC 4F-PCC — Competitive Intelligence Brief

SOC 4F-PCC (SOC 4F-PCC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PAR-1 antagonist. Area: Cardiovascular.

phase 3 PAR-1 antagonist PAR-1 (Protease-Activated Receptor 1) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

SOC 4F-PCC (SOC 4F-PCC) — Takeda. SOC 4F-PCC is a Factor IIa protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin signaling to reduce thrombotic events.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SOC 4F-PCC TARGET SOC 4F-PCC Takeda phase 3 PAR-1 antagonist PAR-1 (Protease-Activated Receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PAR-1 antagonist class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SOC 4F-PCC — Competitive Intelligence Brief. https://druglandscape.com/ci/soc-4f-pcc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: